Moderna stock: Company targets year-end intismeran filing
Published on 11/19/2026 at 16:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOncology plans move toward filing
- Moderna targets a US biologics license application for intismeran by the end of 2026.
- The personalized cancer vaccine showed positive Phase III melanoma data, while renal, bladder and lung cancer studies remain ahead.
- Merck and Moderna plan to share commercialization profits equally, with Merck handling markets outside the United States.
Moderna used the Jefferies Global Healthcare Conference on Wednesday, November 18, to outline the commercial path for intismeran, its personalized cancer vaccine candidate. The company said it is targeting a US Biologics License Application by the end of 2026, according to Investing.com.
Melanoma data anchor the program
Management highlighted positive Phase III melanoma results for intismeran and described the treatment as a potential multibillion-dollar opportunity. The company is also advancing studies in renal cell carcinoma, muscle-invasive bladder cancer and non-small cell lung cancer.
Moderna said an interim renal-cell-carcinoma analysis could arrive within the next 12 months. Final bladder-cancer data are expected in 2027, while an event-driven lung-cancer readout could come in late 2027 or 2028. Additional myeloma data are expected at the American Society of Hematology meeting next month.
Manufacturing and partnership milestones
Moderna said its Marlborough, Massachusetts, facility is operating one manufacturing suite and could add up to six more as demand develops. The company reported a manufacturing success rate above 99% in its clinical experience and said more than 2,000 patients had received treatment across the broader program.
Merck and Moderna plan to co-market intismeran in the United States and share profits equally. Merck is responsible for commercialization outside the United States. Pricing and revenue recognition remain under discussion as the companies prepare for potential regulatory review.
Current Lang and Schwarz quote
Moderna stock traded at 177.61 euros on Lang & Schwarz at 16:31 CET on Thursday, November 19, 2026.
Moderna Inc. market facts
- Company: Moderna Inc.
- ISIN: US60770K1079
- Ticker: MRNA
- Trading venue: Lang & Schwarz
- Quoted price: 177.61 euros at 16:31 CET on November 19, 2026
US biotechnology shares remain sensitive to clinical, regulatory and commercialization milestones. Current market reports provide broader market context.
